BioRay introduces the initiation of its Phase I clinical trial with the first patient for BRY812, a new LIV-1 focused antibody drug conjugate.

Ventyx Biosciences reports outcomes of the second phase study of VTX958 in moderate-to-severe plaque psoriasis patients and delivers a company update.

Monte Rosa Therapeutics unveils preclinical findings. The research indicates that MRT-6160, a VAV1-specific molecular glue breaker, may be effective in treating immune-based and inflammatory disorders.

At SITC 2023, ENB Therapeutics showcased preliminary findings from the first phase of its ENBOLDEN-101 trial for platinum-resistant ovarian cancer.

Qualigen Therapeutics reports the initial dosage in the Phase 1a QN-302 Clinical Study for Advanced or Metastatic Solid Tumors has been administered to the first patient.

The FDA greenlights Lilly's Zepbound™ (tirzepatide) - a potent, new choice for managing persistent weight issues, including obesity or overweight cases with health issues connected to weight.

Amgen has revealed fresh information from the Phase 2 trial of dazodalibep, an experimental drug aimed to treat Sjögren's.

FluoGuide A/S, a precision oncology surgery leader, shared initial results from the phase IIa trial of its leading product, FG001, for head and neck cancer surgeries, at the International Academy of Oral Oncology 2023 conference in South Korea. The study validated the product's efficacy and safety.

MoonLake Immunotherapeutics, a clinical-stage biotech firm, announced encouraging preliminary results from its global Phase 2 ARGO trial. This trial evaluated the efficacy and safety of Nanobody® sonelokimab in patients with active psoriatic arthritis.

Pfizer informed Sosei Group Corporation about initiating a Phase 1 clinical trial with a new oral GLP-1 receptor agonist, PF-06954522, discovered in a joint research venture. Sosei Heptares' StaR® technology was used in the process.

At the 2023 Society for Immunotherapy of Cancer meeting, TILT Biotherapeutics revealed Phase I results for its solo TILT-123 treatment. The firm, a pioneer in cancer immunotherapies, uses this oncolytic virus to activate T-cells, targeting patients with progressive solid tumors.

On October 26th, 2023, KangaBio announced that the FDA has formally approved their clinical trial application for the independently developed KGX101, a fusion protein recombined with IL-12 Fc for intravenous injection. Clinical trials will be held simultaneously in Australia and the US.